89bio Stock (NASDAQ:ETNB)
Previous Close
$7.03
52W Range
$6.43 - $16.63
50D Avg
$8.41
200D Avg
$8.84
Market Cap
$933.60M
Avg Vol (3M)
$879.92K
Beta
0.98
Div Yield
-
ETNB Company Profile
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
ETNB Performance
Peer Comparison
| Ticker | Company |
|---|---|
| TGTX | TG Therapeutics, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| HOOK | HOOKIPA Pharma Inc. |
| PLRX | Pliant Therapeutics, Inc. |
| VKTX | Viking Therapeutics, Inc. |
| INZY | Inozyme Pharma, Inc. |
| AKRO | Akero Therapeutics, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| MREO | Mereo BioPharma Group plc |
| ABOS | Acumen Pharmaceuticals, Inc. |
| MDGL | Madrigal Pharmaceuticals, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| ACLX | Arcellx, Inc. |
| HEPA | Hepion Pharmaceuticals, Inc. |